These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 14675668

  • 1. Distinct subtypes of serous ovarian carcinoma identified by p53 determination.
    Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R.
    Gynecol Oncol; 2003 Dec; 91(3):504-12. PubMed ID: 14675668
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
    Lin J, Du J, Zhang CY, Xie QT, Zhang B, Liu CR.
    Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB.
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [Abstract] [Full Text] [Related]

  • 10. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.
    Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson JA, Isola J, Butzow R.
    Gynecol Oncol; 2004 Jan; 92(1):31-9. PubMed ID: 14751135
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
    Bar JK, Słomska I, Rabczyńki J, Noga L, Gryboś M.
    Int J Gynecol Cancer; 2009 Nov; 19(8):1322-8. PubMed ID: 20009884
    [Abstract] [Full Text] [Related]

  • 14. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I, Seidal T, Sorbe B.
    Int J Gynecol Cancer; 2004 Nov; 14(2):259-70. PubMed ID: 15086725
    [Abstract] [Full Text] [Related]

  • 15. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
    Kalogeraki A, Tamiolakis D, Matalliotaki C, Karvela-Kalogeraki I, Karvelas-Kalogerakis M, Segredakis J, Sinatkas V, Matalliotakis I.
    Rev Med Chir Soc Med Nat Iasi; 2015 Nov; 119(2):454-60. PubMed ID: 26204652
    [Abstract] [Full Text] [Related]

  • 16. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
    Wen J, Shi JL, Shen DH, Chen YX, Song QJ.
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.